News for Sangamo Therapeutics, Inc. (GBY.DE)

Add GBY.DE to watchlist(s)

You Should Create a Watchlist In The First Place.

Price Over Time

Profile

Company Name

Sangamo Therapeutics, Inc.

Symbol

GBY.DE

Currency

EUR

Exchange

Frankfurt Stock Exchange

Head Quarter

United States, Brisbane California

Sector

Healthcare

Industry

Biotechnology

Website

https://www.sangamo.com

ISIN

-

CIK

-

CUSIP

-

UEI

-

LEI

-

Business Description

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A;